CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

E. I. Alexeeva; R. V. Denisova; T. V. Sleptsova; T. M. Bzarova; K. B. Isaeva; E. V. Mitenko; E. G. Chistyakova; A. M. Chomakhidze; N. I. Taybulatov; A. N. Fetisova; O. L. Lomakina; S. I. Valieva

doi:10.15690/pf.v11i2.965

Педиатрическая фармакология (Mar 2014)

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

E. I. Alexeeva,
R. V. Denisova,
T. V. Sleptsova,
T. M. Bzarova,
K. B. Isaeva,
E. V. Mitenko,
E. G. Chistyakova,
A. M. Chomakhidze,
N. I. Taybulatov,
A. N. Fetisova,
O. L. Lomakina,
S. I. Valieva

Affiliations

E. I. Alexeeva: Scientific Center of Children’s Health, Moscow Sechenov First Moscow State Medical University
R. V. Denisova: Scientific Center of Children’s Health, Moscow, Russian Federation
T. V. Sleptsova: Scientific Center of Children’s Health, Moscow, Russian Federation
T. M. Bzarova: Scientific Center of Children’s Health, Moscow, Russian Federation
K. B. Isaeva: Scientific Center of Children’s Health, Moscow, Russian Federation
E. V. Mitenko: Scientific Center of Children’s Health, Moscow, Russian Federation
E. G. Chistyakova: Scientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian Federation
A. M. Chomakhidze: Scientific Center of Children’s Health, Moscow, Russian Federation
N. I. Taybulatov: Scientific Center of Children’s Health, Moscow, Russian Federation
A. N. Fetisova: Scientific Center of Children’s Health, Moscow, Russian Federation
O. L. Lomakina: Scientific Center of Children’s Health, Moscow, Russian Federation
S. I. Valieva: Scientific Center of Children’s Health, Moscow, Russian Federation

DOI: https://doi.org/10.15690/pf.v11i2.965
Journal volume & issue: Vol. 11, no. 2
pp. 88 – 94

Abstract

Read online

The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinumab treatment shortly provided reduction in clinical and laboratory parameters of the disease activity, life quality improvement, development of an inactive disease stage and allowed reducing the prednisolone dose by 90% and avoiding intravenous and intraarticular administration of glucocorticoids.

Published in Педиатрическая фармакология

ISSN: 1727-5776 (Print); 2500-3089 (Online)
Publisher: Union of pediatricians of Russia
Country of publisher: Russian Federation
LCC subjects: Medicine: Pediatrics; Medicine: Therapeutics. Pharmacology
Website: https://www.pedpharma.ru/

About the journal

Abstract

Keywords